Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent

Interleukin-12 (IL-12) has emerged as one of the most potent agents for anti-tumor immunotherapy. However, potentially lethal toxicity associated with systemic administration of IL-12 precludes its clinical application. Here we redesign the molecule in such a way that its anti-tumor efficacy is not...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Pengju, Li, Xiaozhu, Wang, Jiwei, Gao, Dongling, Li, Yuenan, Li, Haoze, Chu, Yongchao, Zhang, Zhongxian, Liu, Hongtao, Jiang, Guozhong, Cheng, Zhenguo, Wang, Shengdian, Dong, Jianzeng, Feng, Baisui, Chard, Louisa S., Lemoine, Nicholas R., Wang, Yaohe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680234/
https://www.ncbi.nlm.nih.gov/pubmed/29123084
http://dx.doi.org/10.1038/s41467-017-01385-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680234/
https://www.ncbi.nlm.nih.gov/pubmed/29123084
http://dx.doi.org/10.1038/s41467-017-01385-8

Ejemplares similares